Trial Profile

A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 04 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PF 08634404 (Primary) ; Atezolizumab; Carboplatin; Etoposide
Indications Small cell lung cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms Symbiotic-Lung04
Sponsors Pfizer

Most Recent Events

21 Apr 2026 According to a Pfizer media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, 2026, in Chicago.
12 Jan 2026 Status changed from not yet recruiting to recruiting.
17 Nov 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com